Chengdu Olymvax Biopharmaceuticals Hits Day High with 5.68% Surge

Chengdu Olymvax Biopharmaceuticals, Inc. has experienced a significant uptick in its stock performance, gaining 5.68% on March 4, 2026. The stock reached an intraday high of CNY 29.20, showcasing its strong market activity. This mid-cap company operates within the Pharmaceuticals & Biotechnology sector and has demonstrated impressive growth metrics, including a 25.38% increase in net sales reported in September. Over the past year, Chengdu Olymvax has delivered remarkable returns of 108.67%, significantly outperforming the China Shanghai Composite, which only saw a 22.49% increase during the same period. The company's performance is further highlighted by a return on capital employed (ROCE) of 6.86% and an exceptionally high interest coverage ratio of 1,289.5, indicating robust financial health. In addition, the company has successfully reduced its raw material costs by 2.66% year-over-year, contributing to its positive financial trajectory. With a market capitalization of CNY 7,820 million and a price-to-earnings ratio of 173.00, Chengdu Olymvax continues to position itself favorably within the competitive landscape of the biotechnology industry.